相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
Daniele Fanale et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)
Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer
Janina Swiderska et al.
DIAGNOSTICS (2022)
Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy
I Lodewijk et al.
NPJ PRECISION ONCOLOGY (2022)
Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer
Georgina E. Wood et al.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2022)
Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer
Daniele Fanale et al.
CANCERS (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
Qin Xu et al.
FRONTIERS IN PHARMACOLOGY (2021)
Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
Laure Chardin et al.
FRONTIERS IN ONCOLOGY (2021)
Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
Daniele Fanale et al.
CANCERS (2021)
Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
Jue Zhu et al.
JOURNAL OF OVARIAN RESEARCH (2021)
Prognostic relevance of high pretreatment CA125 levels in primary serous ovarian cancer
Robert Bachmann et al.
MOLECULAR AND CLINICAL ONCOLOGY (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
Italia Falcone et al.
CANCERS (2020)
A Lymphocyte MicroRNA Signature as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming
Lorena Incorvaia et al.
CANCERS (2020)
CA125 and Ovarian Cancer: A Comprehensive Review
Parsa Charkhchi et al.
CANCERS (2020)
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions
Lorena Incorvaia et al.
ONCOIMMUNOLOGY (2020)
BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells
Kyle K. Payne et al.
SCIENCE (2020)
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
Giuseppe Badalamenti et al.
CELLULAR IMMUNOLOGY (2019)
PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
Fatemeh K. Dermani et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma
Benjamin Bian et al.
ONCOIMMUNOLOGY (2019)
Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study
Lin Wang
JOURNAL OF OVARIAN RESEARCH (2019)
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Lorena Incorvaia et al.
ADVANCES IN THERAPY (2019)
The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies
Oliviero Marinelli et al.
FRONTIERS IN ONCOLOGY (2019)
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?
Lorena Incorvaia et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Checkpoint inhibitors in ovarian cancer: A review of preclinical data
David W. Doo et al.
GYNECOLOGIC ONCOLOGY REPORTS (2019)
BTN3A is a prognosis marker and a promising target for V gamma 9V delta 2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)
Audrey Benyamine et al.
ONCOIMMUNOLOGY (2018)
Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer
Masahiro Takeuchi et al.
IMMUNOLOGY LETTERS (2018)
Prognostic factors in epithelial ovarian cancer: A population-based study
Lin-Chau Chang et al.
PLOS ONE (2018)
High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
Xiaofang Guo et al.
TRANSLATIONAL ONCOLOGY (2018)
Regulation of Human γδ T Cells by BTN3A1 Protein Stability and ATP-Binding Cassette Tracsports
David A. Rhodes et al.
FRONTIERS IN IMMUNOLOGY (2018)
Monoclonal antibodies for the treatment of non-hematological tumors: a safety review
Lidia Rita Corsini et al.
EXPERT OPINION ON DRUG SAFETY (2018)
CA-125 Significance in Cirrhosis and Correlation with Disease Severity and Portal Hypertension: A Retrospective Study
Raja G. R. Edula et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2018)
9PDPD-1 and PD-L1 expression in ovarian cancer
V. Wieser et al.
ANNALS OF ONCOLOGY (2017)
Prognostic significance of PD-L1 in solid tumor An updated meta-analysis
Qianqian Wang et al.
MEDICINE (2017)
Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
Stephan Kruger et al.
ONCOIMMUNOLOGY (2017)
PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges
Xiangjiao Meng et al.
CANCER LETTERS (2017)
Time-dependent ROC curve analysis in medical research: current methods and applications
Adina Najwa Kamarudin et al.
BMC MEDICAL RESEARCH METHODOLOGY (2017)
Prognostication and monitoring of mesothelioma using biomarkers: a systematic review
David T. Arnold et al.
BRITISH JOURNAL OF CANCER (2017)
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma
Chan Kim et al.
BMC CANCER (2016)
Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma
Shang-Yi Huang et al.
ONCOTARGET (2016)
The Significance of Normal Pretreatment Levels of CA125 (< 35 U/mL) in Epithelial Ovarian Carcinoma
Joseph Menczer et al.
RAMBAM MAIMONIDES MEDICAL JOURNAL (2015)
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Ignacio Melero et al.
NATURE REVIEWS CANCER (2015)
Cancer antigen 125 after delivery in women with a normal pregnancy: a prospective cohort study
Pal B. Szecsi et al.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA (2014)
Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer
Christian J. Maine et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Immune modulation by butyrophilins
Heather A. Arnett et al.
NATURE REVIEWS IMMUNOLOGY (2014)
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. A. Ledermann et al.
ANNALS OF ONCOLOGY (2013)
Prognostic value of CA125 in advanced heart failure patients
Silvia Monteiro et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2010)
Peritoneal lavage CEA/CA125 is a prognostic factor for gastric cancer patients
Manabu Yamamoto et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer
Maurie Markman et al.
GYNECOLOGIC ONCOLOGY (2006)
Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma
O Bairey et al.
LEUKEMIA & LYMPHOMA (2003)
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
N Watanabe et al.
NATURE IMMUNOLOGY (2003)
Elevated CA 125 in breast cancer - A sign of advanced disease
LF Norum et al.
TUMOR BIOLOGY (2001)
The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma
DS Chi et al.
GYNECOLOGIC ONCOLOGY (2000)
分享论文
